Company profile for Inversago Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

As a specialty therapeutics, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-acting cannabinoid-1 receptor (CB1) inverse agonists for the treatment of Prader-Willi Syndrome, non-alcoholic steatohepatitis (NASH), type 1 diabetes and other metabolic disorders such as diabetic nephropathy. The mechanism of action of Inversago’s molecules addresses the safety limits associated to firs...
As a specialty therapeutics, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-acting cannabinoid-1 receptor (CB1) inverse agonists for the treatment of Prader-Willi Syndrome, non-alcoholic steatohepatitis (NASH), type 1 diabetes and other metabolic disorders such as diabetic nephropathy. The mechanism of action of Inversago’s molecules addresses the safety limits associated to first generation, centrally-acting CB1 blockers, allowing the company to exploit their full medical potential.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
1 Place Ville Marie Suite 1670 Montreal, Quebec H3B 2B6 Canada
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Inversago was working toward a potential 2024 IPO
Inversago was working toward a potential 2024 IPO

22 Aug 2023

// Kyle LaHucik ENDPTS

https://endpts.com/novo-nordisk-swooped-in-on-inversago-before-the-canadian-biotech-could-test-the-ipo-waters/

Kyle LaHucik ENDPTS
22 Aug 2023

https://www.cnbc.com/2023/08/10/novo-nordisk-to-acquire-inversago-pharma-canadian-obesity-drug-maker-.html

CNBC
11 Aug 2023

https://www.businesswire.com/news/home/20230623384277/en

BUSINESSWIRE
23 Jun 2023

https://www.businesswire.com/news/home/20230608005236/en

BUSINESSWIRE
08 Jun 2023

https://www.businesswire.com/news/home/20230522005106/en

BUSINESSWIRE
22 May 2023

https://www.businesswire.com/news/home/20230124005328/en

BUSINESSWIRE
24 Jan 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty